US 11,806,374 B2
Isolated recombinant oncolytic adenoviruses, pharmaceutical compositions, and uses thereof for drugs for treatment of tumors and/or cancers
Jipo Sheng, Hangzhou (CN); Jin Fu, Hangzhou (CN); Ronghua Zhao, Hangzhou (CN); Yun Qin, Hangzhou (CN); Lin Chen, Hangzhou (CN); Sanmao Kang, Hangzhou (CN); and Fang Hu, Hangzhou (CN)
Assigned to HANGZHOU CONVERD CO., LTD., Hangzhou (CN)
Appl. No. 16/650,863
Filed by HANGZHOU CONVERD CO., LTD., Hangzhou (CN)
PCT Filed Jul. 3, 2018, PCT No. PCT/CN2018/094264
§ 371(c)(1), (2) Date Mar. 26, 2020,
PCT Pub. No. WO2019/062251, PCT Pub. Date Apr. 4, 2019.
Claims priority of application No. 201710899291.6 (CN), filed on Sep. 28, 2017.
Prior Publication US 2020/0276252 A1, Sep. 3, 2020
Int. Cl. A61K 39/23 (2006.01); C12N 15/79 (2006.01); C07H 21/04 (2006.01); A61K 35/761 (2015.01); A61P 35/00 (2006.01); C12N 7/00 (2006.01); C12N 15/113 (2010.01); C12N 15/63 (2006.01); A61K 48/00 (2006.01); C12N 15/64 (2006.01)
CPC A61K 35/761 (2013.01) [A61K 48/005 (2013.01); A61P 35/00 (2018.01); C12N 7/00 (2013.01); C12N 15/113 (2013.01); C12N 15/1135 (2013.01); C12N 15/63 (2013.01); C12N 15/64 (2013.01); C12N 2310/531 (2013.01); C12N 2710/10332 (2013.01); C12N 2710/10343 (2013.01)] 26 Claims
 
1. An isolated recombinant oncolytic adenovirus, wherein the recombinant oncolytic adenovirus is a selectively replicating oncolytic adenovirus and the genome of the recombinant oncolytic adenovirus is integrated with a coding sequence of an exogenous shRNA capable of inhibiting the expression of PDL1 in tumor cells; wherein the coding sequence of the exogenous shRNA is as shown in any one of SEQ ID NOs. 16, 19, and 22.